GLP1R and chronic kidney disease: Consistent with evidence from trials suggesting strong kidney benefit of SGLT2i and weaker benefit of GLP-1 RA, in an analysis restricted to patients with history of CKD stages 3–4, we observed a 25% risk reduction of empagliflozin towards ESKD outcomes relative to GLP-1RA [1–3, 40].